Last reviewed · How we verify

Daprodustat large

GlaxoSmithKline · Phase 3 active Small molecule

Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.

Daprodustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation. Used for Anemia of chronic kidney disease in patients on dialysis, Anemia of chronic kidney disease in non-dialysis patients.

At a glance

Generic nameDaprodustat large
SponsorGlaxoSmithKline
Drug classHIF prolyl hydroxylase inhibitor
TargetProlyl hydroxylase (PHD)
ModalitySmall molecule
Therapeutic areaHematology / Nephrology
PhasePhase 3

Mechanism of action

By inhibiting prolyl hydroxylase enzymes, daprodustat prevents the degradation of hypoxia-inducible factor (HIF), allowing HIF to accumulate and activate genes involved in erythropoietin (EPO) synthesis. This leads to increased red blood cell production without requiring exogenous EPO administration. The mechanism mimics the body's natural response to hypoxia, potentially offering advantages over traditional ESA (erythropoiesis-stimulating agent) therapies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: